Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes

Current Diabetes Reports

Volumn 13, Issue 5, 2013, Pages 663-668

  Unger, Jeff ^a  

^a Unger Primary Care   (United States)

Author keywords

GLP 1 receptor agonists; Hyperglucagonemia; Liraglutide; Type 1 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; INSULIN DETEMIR; LIRAGLUTIDE;

ARTICLE; BLOOD GLUCOSE MONITORING; CELL FUNCTION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN SYNTHESIS; NAUSEA AND VOMITING; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; STOMACH EMPTYING; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; OFF-LABEL USE; RECEPTORS, GLUCAGON;

EID: 84884589027     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0404-x     Document Type: Article

References (30)

1. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab. 1965;25:1317-24.
2. • Unger J, Parkin CG. Type 2 Diabetes: an expanded view of pathophysiology and therapy. Postgraduate Medicine. 2010;122:145-57. Article summarizes the role multiple physiologic deficits associated with type 2 diabetes and the role of incretin mimetic in correcting GLP-1 resistance.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in T2DM. Lancet. 2006;368:1696-705.
4. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-65.
5. • Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297:127-36. This is an interesting prelude to future research, as both Drs. Holst and Vilsboll will address the use of GLP-1 receptor agonists in T1DM patients in the next 2-3 years.
6. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-23.
7. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21:517-33.
8. • Shu L, Matveynko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet. 2009;18:2388-99. β-cell function and survival may be genetically determined.
9. •• DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95. The classic, and often cited work by Dr. DeFronzo in which he discusses the 8 different pathologic defects associated with type 2 diabetes.
10. Triplitt C, DeFronzo RA. Exenatide: first in class incretin mimetic for the treatment of T2DM mellitus. Expert Rev Endocrinol Metab. 2006;1:329-41.
11. •• Unger J. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with T2DM. Mayo Clin Proc. 2010;85(Suppl):S38-49. Written for primary care physicians, author discusses the role of incretin therapeutic options in patients with T2DM.
12. •• Drucker DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of T2DM: evaluation of the risks and benefits. Diabetes Care. 2010;33:428-33. Excellent review of the safety and efficacy of incretin replacement therapies.
13. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750-4.
14. Madsbad S, Krarup T, Regeur L, et al. Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh). 1980;95:359-63.
15. Madsbad S. Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes. Diabetologia. 1983;24:141-7.
16. Gerich JE, Langlos M, Noacco C, et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973;182:171-3.
17. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM. Diabetologia. 1995;38:337-43.
18. •• Downe E, Craig ME, Hing S, et al. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes. Diabetes Care. 2011;34:2368-73. Important paper, which suggests that glycemic variability (as the result of insulinopenia + hyperguconemia) increases one's risk for developing diabetic retinopathy in T1DM.
19. Lugari R, Dell'Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res. 2000;32:424-8.
20. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706-13.
21. Lim GE, Huang GJ, Flora N, et al. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. 2008;150:580-91.
22. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996;19:580-6.
23. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta cell function. Diabetes 2011;60(5):1599-607.
24. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev. 2009;5:266-75. Comprehensive and well referenced review of the rational use of GLP-1 drugs in patients with T1DM.
25. •• Clinical Trials. Gov Web Site: http://www.clinicaltrials. gov/ct2/results?term=liraglutide+and+type+1+diabetes&Search=Search. Accessed April 2, 2013. List of studies, which are currently recruiting patients with T1DM for the evaluation of liraglutide for adjuvant therapy.
26. •• Harrison LB, Mora P, Gregory C, et al. Type 1 diabetes treatment beyond insulin: role of GLP-1 agonists. J Invest Med. 2013;61:40-4. Chart review of 11 patients using liraglutide + insulin pump therapy. Patients noted weight loss, used less daily insulin, and had a lower A1C compared with their individual baseline readings.
27. •• Kielgast U, Krarup T, Holst JJ. Four weeks of treatment with Liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell. Diabetes Care. 2011;34:1463-8. Randomized study showing the safety and efficacy of liraglutide usage in patients with T1DM.
28. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-6.
29. Morrow L, Hompesch M, Guthrie H, et al. Coadministration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metabol. 2011;13:75-80.
30. www.goodrx.com. Accessed May 9, 2013.